no, but they will also kill you (but not by magic)
jesse, what the fuck are you talking about. you can't make efficient antenna for UHF using power transformer toroid
I think it would be comparable to situation where all mRNA is suddenly unusable, ie protein synthesis can't run at all. This would be something like ricin or diphteria toxin poisoning, but instead of being limited to gastrointestinal lining it's spread all over. I'd guess hours to days before anything visible starts happening (symptoms only start to appear when deficit in new protein synthesis becomes noticeable; all protein already made continues to work for sone time)
it's not listed because this is not what is happening
italy for example put bridge construction in that military budget (as critical infrastructure)
also the subtext was "spend that defense budget in america" and this is not happening either for variety of reasons, so it's partial failure already for them
Sell consulting services. Doesn't matter if you're right or wrong, what matters is that you're paid.
is the evil funding man going to eat the gimp pepper
long lost distant cousin of jd vance
only residential wiring uses copper, everything from 350kV down to 400V lines is aluminum, and even in houses aluminum can be used too
firefox at minimum clears the very low bar of not exposing casual user to crypto
no, all people here are 30-40 years old communist programmers from california
Derek Lowe has seen it coming years ago https://www.science.org/content/blog-post/lecanemab-and-alzheimer-s-more-data
But let’s stipulate that the result is real, for the sake of argument. That takes us into the very contentious question of real-world utility. As the NEJM paper says, “A definition of clinically meaningful effects in the primary end point of the CDR-SB score has not been established”. Clinicians are already disagreeing over whether the difference between lecanemab and placebo is something that would even be noticeable. That last link features a quote of Madhav Thambisetty, a neurologist at the National Institute on Aging: “From the perspective of a physician caring for Alzheimer’s patients, the difference between lecanemab and placebo is well below what is considered to be a clinically meaningful treatment effect”. This is not an uncommon take.
And that leads to question 3. A constant problem with these anti-amyloid antibody ideas is the complication of brain edema, an inflammation response that can be serious trouble. The term of the art is “amyloid-related imaging abnormalities with edema or effusions”, ARIA-E. This latest trial kept a constant watch for this, as well it should have, and any such trial also has to keep in mind the possibility of “functional unblinding” as any incidents develop. ARIA-E was noted in 0.8% of the treatment group (and in none of the placebo patients, naturally). Overall, adverse events that were enough to lead to patient discontinuation in the trial occurred in 6.9% of the treatment group and 2.9% of the placebo group. Most seriously, two patients in the treatment group have died from what could well be treatment-related vascular issues
There was also earlier anti-amyloid antibody that got approved despite showing no benefit at all https://www.science.org/content/blog-post/they-don-t-know
fullsquare
joined 9 months ago
it gives enlightened centrist vibe, maybe that's why